Prescribing in pregnancy shows the weaknesses in pharmacovigilance
Authors:
Abstract
Even the most recent of several commendable articles in The BMJ on epilepsy and valproate during pregnancy missed that regulatory agencies should have acted earlier.1 The first report of malformations due to valproate was in 1982.2 Despite many meetings and reports, no action was taken until 2015, when a legal case went public, thanks to a mother whose two children, one after the other, were damaged. She also …Keywords
This publication has 6 references indexed in Scilit:
- Weighing the risks of valproate in women who could become pregnantBMJ, 2018
- Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in PregnancyObstetrics & Gynecology, 2016
- Paucity of data on the safety of drugs for treating depression in pregnancyBMJ, 2016
- Balancing Accelerated Approval for Drugs With Accelerated WithdrawalJAMA Internal Medicine, 2016
- Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regionsPharmacoepidemiology and Drug Safety, 2015
- MATERNAL VALPROIC ACID AND CONGENITAL NEURAL TUBE DEFECTSThe Lancet, 1982